Tracking how long the leukemia medicine calaspargase lasts
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how long the chemotherapy medicine calaspargase stays active in the body. It may help doctors understand how to dose this medicine better for future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 21 years old or younger.
- You must have acute lymphoblastic leukemia or lymphoma.
- You must be receiving treatment with calaspargase (a type of asparaginase chemotherapy).
- You cannot be pregnant.
- You cannot be enrolled in a specific COG trial that includes inotuzumab.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a chemotherapy drug called calaspargase pegol affects blood clotting in children and young adults with leukemia. It will help doctors understand if changes in clotting are common and safe.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
This Phase 3 trial tests a specific treatment protocol for children and teens newly diagnosed with certain types of leukemia, aiming to improve outcomes while managing side effects. You may be invited if your child’s leukemia type and timing fit the study rules.
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
Hear when a new Childhood Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.